Disc Medicine, Inc. to Present Key Data From Hematology Portfolio at EHA 2025 Congress
Disc Medicine Announces Multiple Presentations Across Portfolio At The EHA 2025 Congress
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $75 to $120
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Disc Medicine Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120
Disc Medicine Analyst Ratings
Disc Medicine's Promising Position in MF Anemia Treatment: Buy Rating Affirmed by Evan Seigerman
Analysts Are Bullish on These Healthcare Stocks: Disc Medicine (IRON), Trevi Therapeutics (TRVI)
Express News | Disc Medicine Inc : BMO Raises Target Price to $120 From $112
Buy Rating for Disc Medicine Driven by Promising Bitopertin Prospects and Strategic Advancements
Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation
Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Disc Medicine's Strong Financial Health and Promising Clinical Pipeline Justify Buy Rating
Disc Medicine | 10-Q: Q1 2025 Earnings Report
Disc Medicine Reports Q1 EPS ($1.02), Consensus ($1.07)
Disc Medicine | 8-K: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
Disc Medicine Ended 1Q With $695M in Cash, Cash Equivalents, and Marketable Securities, Which Is Expected to Fund Ops Into 2028 >IRON